The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.

The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.

The anti-Siglec-10 MAb ONC-841 features among the latest crop of first-in-human trial initiations.

A flurry of activity around USP1 inhibition suggests growing interest in this novel DNA damage response mechanism.